Liquid Biopsy Diagnostic Market is Likely to witness profitable growth Over the Next Five Years

The research report is fabricated by Industry experts with 100+ pages of detailed analysis.

Michigan, United States - April 8, 2019 /MarketersMedia/ —

Launching announcement of a new research report on Liquid Biopsy Diagnostic Market. This report, from Stratview Research, studies the global liquid biopsy market over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.

Click here to read the detailed description and TOC: https://www.stratviewresearch.com/422/liquid-biopsy-diagnostic-market.html

The Liquid Biopsy Diagnostic Market: Highlights
According to a report published by The World Health Organization in 2017, the number of breast cancer deaths around the globe is expected to increase. By 2040, more than 991,000 women are expected to die annually of breast cancer across the globe.

The potential for liquid biopsies to lead to early detection of cancer may impact several product lines, mainly critical illness (CI) and medical insurance. Over the past few years, CI has undergone several innovations. Companies now offer staged, multi-pay, and cancer-only plans. A unique selling point of cancer-only and staged CI plans is they cover early-stage cancers as well. Increased near-term utilization of liquid biopsy as part of routine screening tests or diagnostic protocols could lead to higher cancer incidence rates than anticipated. This could impact the pricing assumptions of certain products, especially those offering early-stage cancer benefits.

Recent mainstream news flow has made much of the CancerSEEK diagnostic test, particularly its ability to detect multiple types of cancer from a single blood sample. In reality, further confirmatory tests will be required post-screening before a patient is placed on the current standard of care for their particular cancer. Also, the test’s sensitivity falls to 70% for the purposes of screening certain cancers, which is insufficient to drive standalone clinical decisions. Therefore, considerable further development and validation of liquid biopsy-type platforms are required to establish such a ‘one stop’ diagnostic test. Among the key competitors in liquid biopsy, Biocept, Oncocyte and few others are creating buzz in the market.

Get your copy of free sample pages-click here: https://www.stratviewresearch.com/Request-Sample/422/liquid-biopsy-diagnostic-market.html

Overall, the liquid biopsy (LB) concept complements the personalized medicine approach and provides an innovative way for patient selection in clinical trials, here mutational analysis supports patient eligibility for targeted therapy.

While we do not anticipate that LB will fully replace or directly compete with SB for most diagnostic purposes any time soon, we do very much foresee that LB will complement SB rapidly within the next 3–5 years and will become a tool of choice for dynamic monitoring of patients on treatment or under active surveillance. In many instances, LB will also prompt further imaging workup and/or re-biopsy of tissue lesions.

Report Features
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
• Market structure: Overview, industry life cycle analysis, supply chain analysis
• Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
• Market trend and forecast analysis
• Market segment trend and forecast
• Competitive landscape and dynamics: Market share, Product portfolio, New product launches, etc.
• Attractive market segments and associated growth opportunities
• Emerging trends
• Strategic growth opportunities for the existing and new players
• Key success factors
• Future outlook

ABOUT US
Stratview Research is a global market intelligence firm offering a wide range of services including syndicated market reports, consulting, sourcing intelligence, and customer research.
We have a strong, experienced team of industry veterans and research analysts with a perfect blend of wisdom, knowledge and attitude. We have been serving multiple clients across a wide array of industries.
Our services cover a broad spectrum of industries including Energy, Chemicals, Advanced Materials, Automotive, and Aerospace. We provide research services at the global, regional as well as country level; key regions include Europe, APAC, NA, MEA, RoW.
We are a trusted brand in the research industry with the capability of commissioning complex projects within a short span of time with a high level of accuracy. At Stratview, we believe in building long-term relations with our clients.

To browse through our range of reports in the Healthcare and Life Science industry, refer to the following link:
https://www.stratviewresearch.com/market-reports/Healthcare-and-Life-Sciences.html

Contact Info:
Name: Aditya Joshi
Organization: Stratview Research
Address: United States of America, 400 Renaissance Center, Suite 2600,
Phone: +1-313-307-4176
Website: https://www.stratviewresearch.com

Source URL: https://marketersmedia.com/liquid-biopsy-diagnostic-market-is-likely-to-witness-profitable-growth-over-the-next-five-years/499796

Source: MarketersMedia

Release ID: 499796